Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1944
- Development stage
- Discontinued
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
mRNA-1944 is an investigational therapeutic developed by Moderna that encodes a fully human IgG monoclonal antibody (CHKV-24) targeting the chikungunya virus. Unlike traditional monoclonal antibodies produced in cell culture and administered as proteins, mRNA-1944 uses messenger RNA to instruct the body’s cells to produce the anti-chikungunya antibody directly. The drug consists of two separate mRNAs—one for each chain of the IgG molecule—delivered via Moderna’s proprietary lipid nanoparticle technology. This approach enables rapid and dose-dependent production of functional antibodies in vivo. In clinical studies, administration of mRNA-1944 led to detectable and therapeutically relevant levels of neutralizing antibodies against chikungunya virus in healthy adults[3][6][7]. The program was supported by DARPA funding but has since been discontinued after Phase 1 trials[2].
- Other names
- mRNA encoding Chikungunya antibodyCHKV-24CHKV24CHKV 24
02
Targets
CHIKV E2/E1 (Chikungunya virus envelope protein)CHIKV antigen (Chikungunya virus antigen)
Beyond the preview
Go deeper on mRNA-1944.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1944.